37 results
SC 14D9
EX-99
KNTE
Kinnate Biopharma Inc
4 Mar 24
Tender offer solicitation
5:27pm
forth in your Change in Control and Severance Agreement with the Company (the “CIC Agreement”) or as set forth in Appendix A.
Transaction Bonus … in Control (collectively, a “Transaction”) occurs and you satisfy the Payment Condition for such Transaction, you will be entitled to receive a bonus
SC 14D9
EX-99
KNTE
Kinnate Biopharma Inc
4 Mar 24
Tender offer solicitation
5:27pm
forth in your Change in Control and Severance Agreement with the Company (the “CIC Agreement”) or as set forth in Appendix A.
Transaction Bonus
If a (i … in Control (collectively, a “Transaction”) occurs and you satisfy the Payment Condition for such Transaction, you will be entitled to receive a bonus
SC 14D9
EX-99
KNTE
Kinnate Biopharma Inc
4 Mar 24
Tender offer solicitation
5:27pm
in your Change in Control and Severance Agreement with the Company (the “CIC Agreement”) or as set forth in Appendix A.
Transaction Bonus
If a (i … (collectively, a “Transaction”) occurs and you satisfy the Payment Condition for such Transaction, you will be entitled to receive a bonus (a “Transaction
SC 14D9
KNTE
Kinnate Biopharma Inc
4 Mar 24
Tender offer solicitation
5:27pm
(the “Director Compensation Policy”);
the receipt of transaction bonuses payable to current and former executive officers under certain transaction bonus … in control;
a lump-sum payment equal to the sum of (x) 100% (or 150% in the case of Mr. Farzan) of the executive officer’s target annual bonus as in effect
SC 14D9
EX-99
KNTE
Kinnate Biopharma Inc
4 Mar 24
Tender offer solicitation
5:27pm
in your Change in Control and Severance Agreement with the Company (the “CIC Agreement”) or as set forth in Appendix A.
Transaction Bonus
If a (i … (collectively, a “Transaction”) occurs and you satisfy the Payment Condition for such Transaction, you will be entitled to receive a bonus (a “Transaction
8-K
EX-2.1
3u9qasnsi gknt
16 Feb 24
Entry into a Material Definitive Agreement
9:10am
8-K
t3cx3 o1z
22 Nov 23
Departure of Directors or Certain Officers
4:05pm
8-K
EX-3.1
r5fhdq8z7kc hl4v0h
28 Jul 23
Amendments to Articles of Incorporation or Bylaws
4:06pm
8-K
EX-10.1
pictd7tikfljhjvh yi
7 Jun 21
Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team
8:07am
8-K
14cl20
7 Jun 21
Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team
8:07am
8-K
EX-10.2
79x200
7 Jun 21
Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team
8:07am
DEF 14A
q0xwizgvzr91d99d6
30 Apr 21
Definitive proxy
9:13am
8-K
EX-3.2
f6jkm8brm6gsu 4o
8 Dec 20
Kinnate Biopharma Announces Closing of Initial Public Offering
12:00am
424B4
s20is
3 Dec 20
Prospectus supplement with pricing info
4:48pm
S-1/A
bqpv6yc
30 Nov 20
IPO registration (amended)
6:05am
S-1
EX-10.15
h2z19oswis
13 Nov 20
IPO registration
5:03pm
S-1
EX-3.3
llsilwf1 5babwdchwn6
13 Nov 20
IPO registration
5:03pm